[go: up one dir, main page]

US20050085493A1 - Quinazolinone derivatives and their use as cb agonists - Google Patents

Quinazolinone derivatives and their use as cb agonists Download PDF

Info

Publication number
US20050085493A1
US20050085493A1 US10/503,779 US50377904A US2005085493A1 US 20050085493 A1 US20050085493 A1 US 20050085493A1 US 50377904 A US50377904 A US 50377904A US 2005085493 A1 US2005085493 A1 US 2005085493A1
Authority
US
United States
Prior art keywords
alkyl
alkylene
compound
hydroxyc
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/503,779
Other languages
English (en)
Inventor
Christopher Brain
Edward Dziadulewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Application filed by Individual filed Critical Individual
Publication of US20050085493A1 publication Critical patent/US20050085493A1/en
Priority to US11/823,315 priority Critical patent/US8552015B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel quinazolinone derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
  • the present invention also provides a process for the production of a compound of formula I or an acid addition salt thereof, comprising
  • Process (i) may be performed according to conventional procedures, e.g. as described in example 1. This process (i) is preferred in cases where the particular isocyanate is commercially available or easily prepared. Processes (ii), (iii), (iv) and (v) may be performed according to conventional procedures, e.g. as described in the relevant examples.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • the starting compounds of formulae II, III and V are known or may be produced in analogous manner to known procedures, e.g. as described in example 1.
  • Compounds of formula IV may be produced by reacting a compound of formula II with, e.g. phenyl chloroformate.
  • agents of the invention exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.
  • the agents of the invention exhibit cannabinoid (CB) receptor binding activity. More particularly the agents of the invention are active at the human CB1 and CB2 receptor.
  • Cannabinoid receptor interaction of the agents of the invention may be demonstrated by their ability to displace e.g. [ 3 H]CP55940 from human cannabinoid receptors expressed in, e.g. HEK293 or CHOK1 membranes, e.g. as demonstrated in accordance with the following test methods.
  • the assay mixture comprises 75 ⁇ L of membrane suspension [membranes from HEK293 cells transfected with human CB1 receptors from Receptor Biology, Beltsville, Md.; 133 ⁇ g/mL in assay buffer (50 mM Tris-HCl, 2.5 mM EDTA, 5 mM MgCl 2 5 mg/mL BSA, pH7.4), approx, 10 ⁇ g/well)], 25 ⁇ L WGA-YS beads [Yttrium silicate beads coated with wheat germ agglutinin, Amersham (40 mg/mL, 1 mg/well)], 50 ⁇ L test compound in 4% DMSO and 50 ⁇ L radioligand ⁇ [ 3 H]CP55940 (180 Ci/mmol), New England Nuclear; final concentration 0.125 nM, in assay buffer ⁇ .
  • Non-saturable binding is measured in the presence of 10 ⁇ M (R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)methanone (WIN55,212-2, Tocris).
  • K i values for the CB1 receptor binding assay are in the range of 1 nM to 100 ⁇ M, preferentially from 4 nM to 1 ⁇ M for the agents of the invention.
  • the IC 50 values are calculated in ORIGIN using a logistic fit.
  • the assay mixture comprises 75 ⁇ L of membrane suspension [membranes from CHOK1 cells transfected with human CB2 receptors from Receptor Biology, Beltsville, Md.; 133 ⁇ g/mL in assay buffer (50 mM Tris-HCl, 2.5 mM EDTA, 5 mM MgCl 2 5 mg/mL BSA, pH7.4), approx, 10 ⁇ g/well)], 25 ⁇ L WGA-YS beads [Yttrium silicate beads coated with wheat germ agglutinin, Amersham (40 mg/mL, 1 mg/well)], 50 ⁇ L test compound in 4% DMSO and 50 ⁇ L radioligand ⁇ [ 3 H]CP55940 (180 Ci/mmol), New England Nuclear; final concentration 0.125 nM, in assay buffer ⁇ .
  • Non-saturable binding is measured in the presence of 10 ⁇ M (R)(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)methanone (WIN55,212-2, Tocris).
  • K i values for the CB2 receptor binding assay are also in the range of 1 nM to 100 ⁇ M, preferentially from 4 nM to 1 ⁇ M for the agents of the invention.
  • the IC 50 values are calculated in ORIGIN using a logistic fit.
  • the agents of the invention are thus useful in the treatment or prevention of disease conditions in which cannabinoid receptor activation plays a role or is implicated, e.g. in chronic pain, especially inflammatory, e.g. chronic inflammatory pain, inflammatory diseases for example inflammatory airways disease, e.g. Chronic Obstructive Pulmonary Disease (COPD), or in asthma, rhinitis, inflammatory bowel disease, cystitis, e.g. interstitial cystistis, pancreatitis, uveitis, inflammatory skin disorders and rheumatoid arthritis.
  • COPD Chronic Obstructive Pulmonary Disease
  • Activity specifically as analgesic agents may be confirmed in accordance with standard test methods, e.g. as described in the following test.
  • Hyperalgesia is examined in the model of neuropathic pain induced by partial ligation of the sciatic nerve as described by Seltzer et al. (1990). Briefly, Wistar rats (120-140 g) are anaesthetised, the left sciatic nerve exposed at mid-thigh level through a small incision and 1 ⁇ 3 to 1 ⁇ 2 of the nerve thickness tightly ligated within a 7.0 silk suture. The wound is closed with a single muscle suture and skin clips and dusted with Aureomycin antibiotic powder. The animals are allowed to recover and used 12-15 days following surgery.
  • Mechanical hyperalgesia is assessed by measuring paw withdrawal thresholds to an increasing pressure stimulus placed onto the dorsal surface of the paw using an analgesymeter (Ugo-Basile, Milan) with a cut-off of 250 g. Withdrawal thresholds are measured on both the ipsilateral (ligated) and contralateral (unligated) paw prior to (predose) and then up to 6 h following drug or vehicle administration.
  • % ⁇ ⁇ reversal ipsilateral ⁇ ⁇ threshold ⁇ ⁇ postdose - ipsilateral ⁇ ⁇ threshold ⁇ ⁇ predose contralateral ⁇ ⁇ threshold ⁇ ⁇ predose - ipsilateral ⁇ ⁇ threshold ⁇ ⁇ predose ⁇ 100
  • Potency is expressed as D 50 value, i.e. the dose of compound necessary to produce 50% reversal of hyperalgesia.
  • D 50 values are in the range of 0.1 mg/kg to 100 mg/kg for the agents of the invention.
  • Activity specifically as CB1 agonists may be confirmed in accordance with standard test methods, e.g. as described in the following test.
  • G-protein activation is used as a functional measure of receptor-ligand association for G-protein coupled receptors.
  • the basic mechanism behind G-protein activation is the exchange of bound guanosine 5′-diphosphate (GDP) for guanosine 5′-triphosphate (GTP).
  • GDP bound guanosine 5′-diphosphate
  • GTP guanosine 5′-triphosphate
  • GTP ⁇ S a radioactive, non-hydrolyzable form of GTP, such as guanosine 5′-O-(3-[ 35 S]thiophosphate ([ 35 S]GTP ⁇ S)
  • G-protein activation is assessed by measuring the accumulation of membrane-bound radioactivity in response to receptor activation.
  • the assay buffer comprises 25 mM HEPES (2.98 g/0.5 L), 10 mM anhydrous MgCl 2 (476 mg/0.5 L), 100 mM NaCl (2.92 g/0.5 L) and 0.1% Bovine Serum Albumin (0.5 g/0.5 L).
  • 10 ⁇ GTP ⁇ S Tetralithium salt
  • G-8634 1 mM stock, dilute 1:10 for 100 ⁇ M); 10 ⁇ [ 35 S]-GTP ⁇ S (NEN Life Science, catalogue no. NEG030H, 250 ⁇ Ci/20 ⁇ L; 10 ⁇ M stock, dilute 1:20,000 for 0.5 nM); hCB1 receptor membrane (HEK293 cells; Receptor Biology Inc, catalogue no.
  • SPA Scintillation Proximity Assay
  • Non-specific binding is determined using 10 ⁇ M GTP ⁇ S, and this is subtracted from all values. Basal binding is assayed in the absence of agonist and in the presence of GDP. The stimulation by agonist is defined as a percentage increase above basal levels, i.e., ⁇ [cpm (agonist) ⁇ cpm (no agonist)]/cpm (no agonist) ⁇ 100
  • E max is the maximal activity of the test compound compared to that of WIN55,212-2 on the same plate.
  • EC 50 values are in the range of 1 nM to 50 ⁇ M, preferentially from 2 nM to 3 ⁇ M for the agents of the invention.
  • E max values are in the range of 52% to 180%, preferentially from 80% to 180% for the agents of the invention.
  • the agents of the invention are thus in particular useful as cannabinoid receptor agonists, e.g. for the treatment of pain of various genesis or aetiology and as anti-inflammatory and/or anti-oedemic agents for the treatment of inflammatory reactions, diseases or conditions, as well as for the treatment of allergic responses.
  • cannabinoid receptor agonists e.g. for the treatment of pain of various genesis or aetiology
  • anti-inflammatory and/or anti-oedemic agents for the treatment of inflammatory reactions, diseases or conditions, as well as for the treatment of allergic responses.
  • analgesic anti-inflammatory profile they are useful for the treatment of inflammatory pain, for the treatment of hyperalgesia and, in particular, for the treatment of severe chronic pain. They are, for example, useful for the treatment of pain, inflammation and/or oedema consequential to trauma, e.g. associated with burns, sprains, fracture or the like, subsequent to surgical intervention, e.g.
  • analgesics as post-operative analgesics, as well as for the treatment of inflammatory pain of diverse genesis, e.g. for the treatment of bone and joint pain (osteoarthritis), rheumatoid arthritis, rheumatic disease, teno-synovitis, gout, cancer pain, myofascial pain (muscular injury, fibromyalgia), lower back pain, chronic neuropathic pain, e.g. diabetic neuropathy, phantom limb pain and perioperative pain (general surgery, gynecologic surgery). They are further suitable as analgesics for the treatment of pain associated with, e.g., angina, menstruation or cancer. As anti-inflammatory/anti-oedema agents, they are further useful, e.g., for the treatment of inflammatory skin disorders, for example psoriasis and eczema.
  • the agent of the invention are also useful for the treatment of chronic psychiatric diseases, such as depressions, depression and bipolar disorders, e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired.
  • chronic psychiatric diseases such as depressions, depression and bipolar disorders, e.g. manic-depressive psychoses, extreme psychotic states e.g. mania, schizophrenia, and excessive mood swings where behavioural stabilization is desired.
  • the compound is indicated in ADHD (attention deficit hyperactivity disorders) and other attention disorders, e.g. autism, anxiety states, generalized anxiety and agoraphobia, as well as those behavioural states characterized by social withdrawal e.g. negative symptoms, and for the treatment and prevention of neurodegenerative disease, e.g. Alzheimer, Parkinson.
  • ADHD attention deficit hyperactivity disorders
  • other attention disorders e.g. autism, anxiety states, generalized anxiety and agoraphobia
  • neurodegenerative disease e.g. Alzheimer
  • the agents of the invention are also useful as smooth muscle relaxants, e.g. for the treatment of spasm of the gastro-intestinal tract or uterus, e.g. in the therapy of Crohn's disease, ulcerative colitis or pancreatitis and for the treatment of muscle spasticity and tremor in e.g. multiple sclerosis.
  • the agents of the invention are also useful in the treatment of ocular disorders selected from the group consisting of glaucoma, normal tension glaucoma and neurodegenerative diseases conditions of the retina and the optic nerve, especially in patients presenting risk factors for glaucoma, such as but not exclusively high intraocular pressure, family history of glaucoma, glaucoma in the contralateral eye and high myopia.
  • treatment refers to both prophylactic or preventative treatment as well as curative or disease modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
  • the appropriate dosage of the agents of the invention will, of course, vary depending upon, for example, the host, the mode of administration and the nature and severity of the condition being treated as well as the relative potency of the particular agent of the invention employed.
  • the amount of active agent required may be determined on the basis of known in vitro and in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect.
  • satisfactory results in animals are indicated to be obtained at daily dosages of from about 0.01 to about 20.0 mg/kg p.o.
  • an indicated daily dosage is in the range of from about 0.7 to about 1400 mg/day p.o., e.g.
  • Oral dosage forms accordingly suitably comprise from about 0.2 to about 700 mg of an agent of the invention admixed with an appropriate pharmaceutically acceptable diluent or carrier.
  • agents of the invention may alternatively be administered e.g. topically in the form of a cream, gel or the like for example for the treatment of conditions of the skin as hereinbefore described or by inhalation, e.g. in dry powder form, for example for the treatment of asthma.
  • compositions comprising an agent of the invention include, e.g. a solid dispersion, an aqueous solution, e.g. containing a solubilising agent, a microemulsion and a suspension of, e.g. a hydrochloride salt of a compound of formula I in the range of from 0.1 to 1%, e.g. 0.5%.
  • the composition may be buffered to a pH in the range of, e.g. from 3.5 to 9.5, e.g. to pH 4.5, by a suitable buffer.
  • the agents of the invention are also useful as research chemicals.
  • the agents of the invention can be administered in vivo either alone or in combination with other pharmaceutical agents effective in the treatment of diseases and conditions in which CB1 or CB2 receptor activation plays a role or is implicated including cyclooxygenase-2 (COX-2) inhibitors, such as specific COX-2 inhibitors (e.g. celecoxib and rofecoxib) and nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. acetylsalicylic acid, propionic acid derivatives), vanilloid receptor antagonists, tricyclic antidepressants (e.g.
  • COX-2 cyclooxygenase-2
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • acetylsalicylic acid, propionic acid derivatives e.g. acetylsalicylic acid, propionic acid derivatives
  • vanilloid receptor antagonists e.g.
  • anticonvulsants e.g. gabapentin
  • GABA B agonists e.g. L-baclofen
  • compositions for separate administration of the combination partners and for the administration in a fixed combination i.e. a single galenical composition comprising at least two combination partners
  • a single galenical composition comprising at least two combination partners can be prepared in a manner known per se and are thus suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application.
  • Novel pharmaceutical compositions contain, for example, from about 0.1% to about 99.9%, preferably from about 20% to about 60%, of the active ingredients.
  • Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as sugar-coated tablets, tablets, capsules or suppositories, and furthermore ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar-coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.
  • a therapeutically effective amount of each of the combination partners may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination.
  • the method of delay of progression or treatment of a proliferative disease according to the invention may comprise (i) administration of the combination partner (a) in free or pharmaceutically acceptable salt form and (ii) administration of a combination partner (b) in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily dosages corresponding to the amounts described herein.
  • the individual combination partners can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • administering also encompasses the use of a pro-drug of a combination partner that converts in vivo to the combination partner as such.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term “administering” is to be interpreted accordingly.
  • each of the combination partners employed may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, the severity of the condition being treated.
  • the dosage regimen is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient.
  • a physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites. In general, satisfactory results in animals are indicated to be obtained at daily dosages of from about 0.01 to about 20.0 mg/kg p.o.
  • an indicated daily dosage is in the range of from about 0.7 to about 1400 mg/day p.o., e.g. from about 50 to 200 mg, conveniently administered once or in divided doses up to 4 ⁇ per day or in sustained release form.
  • Oral dosage forms accordingly suitably comprise from about 0.2 to about 700 mg.
  • the present invention also provides:
  • the preferred compound of formula I for use in accordance with the invention is that of Example 2.
  • the D 50 value in the neuropathic pain model of test III for the compound of example 2 is 0.5 mg/kg p.o.
  • the yellow-brown reaction mixture is treated with ice (3 kg) and extracted with tert-butyl methyl ether (2 ⁇ 15 L).
  • the organic phase is additionally extracted with brine (5 L).
  • Concentrated HCl solution (2.5 L) is added to the aqueous phase until a pH of 1 was achieved, maintaining the temperature below 30° C. with addition of ice as necessary.
  • the acidified aqueous layer is extracted with ethyl acetate (2 ⁇ 3 L), and the organic phases were backwashed with brine (2 L).
  • the combined organic phases are dried over anhydrous Na 2 SO 4 , filtered and the solvent removed under reduced pressure to afford the title compound as a white crystalline solid (377 g, 94%).
  • the organic phase is back-extracted with water (0.5 L). Concentrated HCl solution (2.5 L) is added to the combined aqueous phases until a pH of 1 is achieved, maintaining the temperature below 30° C. with addition of ice as necessary.
  • the acidified aqueous layer is extracted with ethyl acetate (2 ⁇ 3 L), and the organic phases are backwashed with brine (2 L).
  • the combined organic phases are dried over anhydrous Na 2 SO 4 , filtered and the solvent concentrated to a volume of ca. 1 L.
  • the yellow ethyl acetate solution is diluted with hexane (2 L) and stored at 0° C. for 1 h.
  • the resulting white suspension is filtered, thoroughly washed with hexane/ethyl acetate (8:2) and dried at 40° C. to constant weight to afford the title product as a white crystalline solid (194 g, 84.9%). A further 17.8 g (7.8%) can be recovered from the mother liquor.
  • reaction mixture is evaporated in vacuo and the residue is partitioned between water and ethyl acetate.
  • the organic phase is separated and the aqueous phase is extracted with ethyl acetate.
  • the combined organic phases are washed with saturated aqueous NaHCO 3 solution, brine and then dried over anhydrous MgSO 4 . Evaporation in vacuo provides the title compound as pale yellow crystals (16.91 g, 0.078 mol, 95%).
  • the reaction mixture is stirred at room temperature for 5 minutes and then heated to reflux. After 45 minutes LCMS analysis indicates that the reaction is complete.
  • the suspension is cooled to room temperature and the solution phase is decanted from the solid material.
  • the solution and solid material are worked-up separately.
  • the toluene solution is portioned between ethyl acetate and saturated aqueous NaHCO 3 solution with vigorous stirring to give a clear biphasic solution.
  • the organic and aqueous phases are separated and the aqueous phase is extracted ( ⁇ 2) with ethyl acetate.
  • the organic phases are combined, dried over anhydrous Na 2 SO 4 , and evaporated in vacuo to give an orange oil.
  • the solid material is stirred vigorously with ethyl acetate and saturated aqueous NaHCO 3 solution to give a clear biphasic solution.
  • the organic and aqueous phases are separated and the aqueous phase is extracted ( ⁇ 2) with ethyl acetate.
  • the organic phases are combined, dried over anhydrous Na 2 SO 4 , and evaporated in vacuo to give an orange oil. Trituration of the orange oils with diethyl ether provides yellow solids, which are removed by filtration, washed with diethyl ether and air-dried to provide the title compound (20 g, 0.037 mol, 53%).
  • the residue is partitioned between ethyl acetate and 2 M HCl.
  • the organic phase is separated, dried over anhydrous Na 2 SO 4 , and evaporated to give an off-white foam which is dried at high vacuum.
  • the foam is dissolved in anhydrous THF (10 mL) and ethanolamine (2 mL, 33 mmol) is added.
  • the reaction mixture is stirred overnight at room temperature under argon. TLC/LCMS analysis indicates completion of the reaction.
  • the reaction mixture is evaporated in vacuo to dryness and the residue is partitioned between dichloromethane and 2 M HCl.
  • the organic phase is separated, dried over anhydrous Na 2 SO 4 and evaporated in vacuo to give an orange oil.
  • reaction mixture Upon cooling to room temperature, the reaction mixture is poured onto saturated sodium hydrogen carbonate solution and extracted with chloroform. The chloroform extracts are combined, washed with brine and dried over anhydrous MgSO 4 . The solvent is removed under reduced pressure and the residue is purified by flash chromatography over silica gel (initial eluent: 19:1 cyclohexane:ethyl acetate; final eluent: 7:3 cyclohexane:ethyl acetate) to afford the title compound.
  • the solvent is removed under reduced pressure, and the residue is dissolved in water and washed with ethyl acetate.
  • the aqueous layer is acidified to pH2 with concentrated hydrochloric acid and this is extracted with ethyl acetate.
  • the organic phases are combined, dried over anhydrous MgSO 4 and the solvent is removed under reduced pressure to afford the title compound, which is used without further purification.
  • the solvent is removed under reduced pressure and the residue is dissolved in ethyl acetate.
  • the ethyl acetate solution is washed sequentially with 2M hydrochloric acid, saturated sodium hydrogen carbonate solution and brine. After drying over anhydrous MgSO 4 , the solvent is removed under reduced pressure and the residue is purified by preparative high-performance liquid chromatography to afford the title product.
  • reaction mixture is evaporated in vacuo to give a brown solid, which is suspended in diethyl ether/dichloromethane and stirred overnight. Filtration, followed by washing with dichloromethane then ether and drying in vacuo provides the title compound as a sandy brown solid.
  • a white precipitate is formed.
  • the reaction mixture is heated to 80° C. for 2 h and is then evaporated and dried at high vacuum.
  • To the residue is added propanol (30 mL) and dichloromethane (1 mL) to give a solution, which is stirred at room temperature overnight.
  • the reaction mixture is evaporated in vacuo to dryness and the residue is partitioned between dichloromethane and 2.0 M hydrochloric acid.
  • the organic phase is dried (Na 2 SO 4 ) and evaporated in vacuo to give a yellow oil.
  • the oil is dissolved in THF (5 mL), ethanolamine (1 mL) is added and the reaction mixture is stirred overnight at room temperature.
  • reaction mixture is evaporated in vacuo to dryness and the residue is partitioned between dichloromethane and 2.0 M hydrochloric acid.
  • organic phase is dried (Na 2 SO 4 ) and evaporated in vacuo to give a yellow oil.
  • Automated gradient elution (10-100% ethyl acetate in hexanes) flash chromatography provides the title compound as a pale yellow foam.
  • the yellow-brown reaction mixture is treated with ice (3 kg) and extracted with tert-butyl methyl ether (2 ⁇ 15 L).
  • the organic phase is additionally extracted with brine (5 L).
  • Concentrated HCl solution (2.5 L) is added to the aqueous phase until a pH of 1 was achieved, maintaining the temperature below 30° C. with addition of ice as necessary.
  • the acidified aqueous layer is extracted with ethyl acetate (2 ⁇ 3 L), and the organic phases were backwashed with brine (2 L).
  • the combined organic phases are dried over anhydrous Na 2 SO 4 , filtered and the solvent removed under reduced pressure to afford the title compound as a white crystalline solid.
  • the crude product is dissolved in hexane/ethyl acetate (1 L, 1:1) and purified by filtration through silica gel (6 kg), eluting with hexane/ethyl acetate (8:1) to afford the title product as a yellow, waxy solid.
  • the organic phase is back-extracted with water (0.5 L). Concentrated HCl solution (2.5 L) is added to the combined aqueous phases until a pH of 1 is achieved, maintaining the temperature below 30° C. with addition of ice as necessary.
  • the acidified aqueous layer is extracted with ethyl acetate (2 ⁇ 3 L), and the organic phases are backwashed with brine (2 L).
  • the combined organic phases are dried over anhydrous Na 2 SO 4 , filtered and the solvent concentrated to a volume of ca. 1 L.
  • the yellow ethyl acetate solution is diluted with hexane (2 L) and stored at 0° C. for 1 h.
  • the resulting white suspension is filtered, thoroughly washed with hexane/ethyl acetate (8:2) and dried at 40° C. to constant weight to afford the title product as a white crystalline solid. A further amount can be recovered from the mother liquor.
  • reaction mixture is evaporated in vacuo and the residue is partitioned between water and ethyl acetate.
  • the organic phase is separated and the aqueous phase is extracted with ethyl acetate.
  • the combined organic phases are washed with saturated aqueous NaHCO 3 solution, brine and then dried over anhydrous MgSO 4 . Evaporation in vacuo provides the title compound as pale yellow crystals.
  • the reaction mixture is stirred at room temperature for 5 minutes and then heated to reflux. After 45 minutes LCMS analysis indicates that the reaction is complete.
  • the suspension is cooled to room temperature and the solution phase is decanted from the solid material.
  • the solution and solid material are worked-up separately.
  • the toluene solution is partitioned between ethyl acetate and saturated aqueous NaHCO 3 solution with vigorous stirring to give a clear biphasic solution.
  • the organic and aqueous phases are separated and the aqueous phase is extracted ( ⁇ 2) with ethyl acetate.
  • the organic phases are combined, dried over anhydrous Na 2 SO 4 , and evaporated in vacuo to give an orange oil.
  • the solid material is stirred vigorously with ethyl acetate and saturated aqueous NaHCO 3 solution to give a clear biphasic solution.
  • the organic and aqueous phases are separated and the aqueous phase is extracted ( ⁇ 2) with ethyl acetate.
  • the organic phases are combined, dried over anhydrous Na 2 SO 4 , and evaporated in vacuo to give an orange oil. Trituration of the orange oil with diethyl ether provides a yellow solid, which is removed by filtration, washed with diethyl ether and air-dried to provide the title compound.
  • reaction mixture is stirred at room temperature overnight.
  • the solvent is removed in vacuo and the residue is partitioned between water and ethyl acetate.
  • the aqueous phase is extracted three times with ethyl acetate and the combined organic extracts are dried (Na 2 SO 4 ) and evaporated in vacuo.
  • Automated gradient elution (0-80% ethyl acetate in hexanes) flash chromatography provides the title compound as a white solid.
  • reaction mixture is allowed to warm to room temperature over 2 h, after which bromomethyl cyclobutane (0.055 mL, 0.488 mmol) is added. After stirring overnight at room temperature, potassium iodide (catalytic quantity) is added and the reaction mixture is heated in a sealed tube to 90° C. in a single mode microwave instrument for 1 h 25 min. The solvent is removed in vacuo and the residue is partitioned between saturated aqueous sodium hydrogen carbonate and ethyl acetate. The organic phase is dried (Na 2 SO 4 ) and evaporated in vacuo. Automated gradient elution (10-80% ethyl acetate in hexanes) flash chromatography provides the title compound as a white solid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/503,779 2002-02-06 2003-02-05 Quinazolinone derivatives and their use as cb agonists Abandoned US20050085493A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/823,315 US8552015B2 (en) 2002-02-06 2007-06-26 Quinazolinone derivatives and their use as CB agonists

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0202755.5 2002-02-06
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0213285.0 2002-06-10
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221460.9 2002-09-16
GB0221459.1 2002-09-16
PCT/EP2003/001140 WO2003066603A1 (en) 2002-02-06 2003-02-05 Quinazolinone derivatives and their use as cb agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/823,315 Continuation US8552015B2 (en) 2002-02-06 2007-06-26 Quinazolinone derivatives and their use as CB agonists

Publications (1)

Publication Number Publication Date
US20050085493A1 true US20050085493A1 (en) 2005-04-21

Family

ID=27739227

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/503,779 Abandoned US20050085493A1 (en) 2002-02-06 2003-02-05 Quinazolinone derivatives and their use as cb agonists
US11/823,315 Expired - Fee Related US8552015B2 (en) 2002-02-06 2007-06-26 Quinazolinone derivatives and their use as CB agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/823,315 Expired - Fee Related US8552015B2 (en) 2002-02-06 2007-06-26 Quinazolinone derivatives and their use as CB agonists

Country Status (21)

Country Link
US (2) US20050085493A1 (es)
EP (2) EP2319839A1 (es)
JP (2) JP4428479B2 (es)
KR (1) KR100954626B1 (es)
CN (1) CN100579968C (es)
AR (1) AR038483A1 (es)
AT (1) ATE551329T1 (es)
AU (1) AU2003210212A1 (es)
BR (1) BR0307461A (es)
CA (1) CA2471974C (es)
CO (1) CO5601021A2 (es)
EC (1) ECSP045219A (es)
ES (1) ES2384967T3 (es)
MX (1) MXPA04007641A (es)
MY (1) MY143958A (es)
NO (1) NO328305B1 (es)
NZ (1) NZ571615A (es)
PE (1) PE20030867A1 (es)
PL (1) PL370657A1 (es)
TW (1) TW200306839A (es)
WO (1) WO2003066603A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090029984A1 (en) * 2005-07-11 2009-01-29 N.V. Organon Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist)
US7728141B2 (en) 2003-11-04 2010-06-01 Merck Sharp & Dohme Corp. Substituted naphthyridinone derivatives

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103336T2 (tr) 1999-03-17 2002-04-22 Astrazeneca Ab Amid türevleri.
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276295A (en) * 1978-12-19 1981-06-30 Masayuki Ishikawa 3-Aromatic moiety substituted-4(3H)-quinazolinones, process for production thereof, and use thereof
US4451467A (en) * 1981-01-16 1984-05-29 Masayuki Ishikawa 4(3H)-Quinazolinone derivatives, process for production thereof, and pharmaceutical compositions comprising said compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (es) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
EP0639986A1 (en) * 1992-05-13 1995-03-01 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
EP0887340A4 (en) 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276295A (en) * 1978-12-19 1981-06-30 Masayuki Ishikawa 3-Aromatic moiety substituted-4(3H)-quinazolinones, process for production thereof, and use thereof
US4451467A (en) * 1981-01-16 1984-05-29 Masayuki Ishikawa 4(3H)-Quinazolinone derivatives, process for production thereof, and pharmaceutical compositions comprising said compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728141B2 (en) 2003-11-04 2010-06-01 Merck Sharp & Dohme Corp. Substituted naphthyridinone derivatives
US20090029984A1 (en) * 2005-07-11 2009-01-29 N.V. Organon Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist)

Also Published As

Publication number Publication date
NO20043580L (no) 2004-09-21
KR100954626B1 (ko) 2010-04-27
JP2009149658A (ja) 2009-07-09
ES2384967T3 (es) 2012-07-16
PL370657A1 (en) 2005-05-30
NZ571615A (en) 2010-01-29
CN100579968C (zh) 2010-01-13
AU2003210212A1 (en) 2003-09-02
MXPA04007641A (es) 2004-11-10
TW200306839A (en) 2003-12-01
CA2471974A1 (en) 2003-08-14
NO20043580D0 (no) 2004-08-27
CA2471974C (en) 2011-11-22
NO328305B1 (no) 2010-01-25
ATE551329T1 (de) 2012-04-15
JP2005522439A (ja) 2005-07-28
HK1079518A1 (zh) 2006-04-07
EP2319839A1 (en) 2011-05-11
EP1472234A1 (en) 2004-11-03
PE20030867A1 (es) 2003-12-04
BR0307461A (pt) 2004-11-09
MY143958A (en) 2011-07-29
CN1628104A (zh) 2005-06-15
ECSP045219A (es) 2004-09-28
WO2003066603A1 (en) 2003-08-14
AR038483A1 (es) 2005-01-19
KR20040083501A (ko) 2004-10-02
US8552015B2 (en) 2013-10-08
JP4428479B2 (ja) 2010-03-10
US20070265285A1 (en) 2007-11-15
CO5601021A2 (es) 2006-01-31
EP1472234B1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
US8552015B2 (en) Quinazolinone derivatives and their use as CB agonists
US6372740B1 (en) 2-aryl-8-oxodihydropurine derivative, process for the producing the same, medicinal compositions containing the same, and intermediates thereof
RU2396261C2 (ru) Производные хиназолинона, полезные в качестве ванилоидных антагонистов
US6562846B2 (en) Bisarylimidazolyl fatty acid amide hydrolase inhibitors
JP3814125B2 (ja) ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
RU2727194C2 (ru) Гетероциклические соединения для лечения заболевания
AU2020256301A1 (en) Fused bicyclic compounds for the treatment of disease
AU2011237421B2 (en) Inverse agonists and neutral antagonists for the TSH receptor
US20080318960A1 (en) PAR2-modulating compounds and their use
US8048877B2 (en) Guanidine derivatives and their medical use
EP1568697A1 (en) 1,3-benzothiazinone derivatives, process for producing the same and use thereof
AU2007202781B2 (en) Quinazolinone derivatives and their use as CB agonists
ZA200404959B (en) Quinazolinone derivatives and their use as CB agonists
HK1079518B (en) Quinazolinone derivatives and their use as cb agonists
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
CZ20001981A3 (cs) 2-Aryl-8-oxodihydropurinové deriváty, způsob jejich přípravy, farmaceutické prostředky které je obsahují a jejich meziprodukty
HK1245795B (en) Fused bicyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION